ImmunoSig

Executive Summary

ImmunoSig is a UK-based biotechnology company that integrates advanced peptide and protein microarray technology with machine learning to provide detailed immunoprofiling services. Founded in 2018, the company assists vaccine and biologics developers in analyzing complex immune responses, thereby de-risking pipelines and accelerating decision-making. Its platform is designed to handle multi-component vaccines and complex biologics, translating antibody binding patterns into actionable insights. ImmunoSig operates at the intersection of immunology, AI/machine learning, and diagnostics, offering a unique value proposition in the rapidly evolving field of immunoprofiling. By enabling a deeper understanding of immune responses, the company aims to improve the success rate of therapeutic development and reduce time-to-market for novel vaccines and biologics.

Upcoming Catalysts (preview)

• Q3 2026Partnership with major vaccine developer40% success
• Q4 2026Publication of platform validation study in peer-reviewed journal60% success
• Q2 2026Series A funding round closure50% success